07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Megabios management update

Megabios Corp. , Burlingame, Calif.   Business: Gene/Cell therapy   Hired: Beatrice Langton-Webster as director of life sciences; formerly the head of oncology strategic research at Berlex Biosciences.   Hired: Ralph Niven as director of...
07:00 , Sep 8, 2008 |  BC Week In Review  |  Clinical News

Seven-day contraceptive patch: Phase II data

Top-line data from an open-label, cross-over pharmacokinetic study in 39 patients showed that AG-200-15 produced EE and LNG levels that were less than with oral Levlen LNG/EE. No serious adverse events were observed. Levlen is...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Company News

Agile Therapeutics management update

Agile Therapeutics Inc. , Princeton, N.J.   Business: Genitourinary   Hired: Jeffrey Frick as CBO, formerly head of the women’s health marketing group at Berlex Laboratories Inc. (now Bayer AG’s Bayer HealthCare Pharmaceuticals unit)  ...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

Bioject management update

Bioject Medical Technologies Inc. (BJCT), Tualatin, Ore.   Business: Drug delivery   Hired: Ralph Makar as president and CEO, formerly VP and general manager of the therapeutics business unit at Schering AG 's Berlex Laboratories...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Company News

Agile Therapeutics management update

Agile Therapeutics Inc. , Princeton, N.J.   Business: Genitourinary   Hired: Marie Foegh as CMO, formerly VP of medical affairs, strategy and development for female healthcare at Schering AG 's Berlex Inc. unit  ...
07:00 , Apr 9, 2007 |  BC Week In Review  |  Company News

Bayer pharmaceuticals news

BAY’s Bayer Healthcare LLC division established U.S. headquarters in Wayne, N.J. The move incorporates Berlex Inc., which BAY received when it acquired Schering AG (see BioCentury, July 17, 2006). Bayer AG (FSE:BAY; BAY), Leverkusen, Germany...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Company News

Favrille, Bayer deal

BAY’s Berlex Laboratories Inc. subsidiary and FVRL partnered to use FVRL’s FavId in combination with Berlex’s Leukine sargramostim to treat B cell non-Hodgkin’s lymphoma (NHL). Each company received rights to market the combination, which is...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Company News

VioQuest management update

VioQuest Pharmaceuticals Inc. (VQPH), Basking Ridge, N.J.   Business: Cancer, Chemistry, Supply/Service   Hired: Edward Bradley as CSO, formerly CMO at Schering AG 's Berlex Laboratories Inc. subsidiary  ...
08:00 , Jan 29, 2007 |  BioCentury  |  Politics, Policy & Law

Firing up for FOBs

Generic drug and biotech companies maneuvered behind the scenes last week to drum up high level support for their positions on follow-on biologics legislation. The issue will break out into the daylight soon with the...
08:00 , Dec 18, 2006 |  BC Week In Review  |  Clinical News

Campath alemtuzumab: Phase III data

In the open-label, international Phase III CAM307 trial in 297 treatment-naïve patients, Campath met the primary endpoint of higher PFS vs. chlorambucil. Campath reduced the risk of disease progression or death by 42% vs. chlorambucil....